What is Baijin Life Science Holdings Limited (MNNGF) stock price today?

Baijin Life Science Holdings Limited (MNNGF) is currently trading at $0.08, up 0% today.

What is MNNGF P/E ratio?

Baijin Life Science Holdings Limited's P/E ratio is -22.39. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MNNGF return on equity (ROE)?

Baijin Life Science Holdings Limited's return on equity (ROE) is -23.23%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Baijin Life Science Holdings Limited's market cap?

Baijin Life Science Holdings Limited has a market capitalization of $74.58M.

OTC · Drug Manufacturers - Specialty & Generic

Baijin Life Science Holdings Limited (MNNGF) Stock

$0.08 +0.00% OTC: MNNGF Consumer Cyclical

Valuation

Metric	Value
Price	$0.08
Market Cap	$74.58M
P/E Ratio	-22.39
P/B Ratio	5.99
P/S Ratio	9.40
EPS (TTM)	$-0.06
52-Week High	$0.08
52-Week Low	$0.05
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-23.23%
ROA	-14.32%
ROCE	-16.87%
Gross Margin	7.46%
Operating Margin	-37.74%
Net Margin	-42.40%
Debt/Equity	0.15
Current Ratio	2.97

Annual Financials (USD)

Metric	2022	2023	2024	2025	2026
Revenue	$63.0M	$87.0M	$54.0M	$136.0M	$89.0M
Operating Profit	$-11.0M	$10.0M	$-10.0M	$-2.0M	$-48.0M
Net Profit	$-15.0M	$9.0M	$-7.0M	$0	$-38.0M
EPS	$-0.04	$0.01	$-0.01	$0.00	$-0.06
Op Margin	-17.7%	11.0%	-17.8%	-1.5%	-53.8%

Balance Sheet (USD)

Metric	2022	2023	2024	2025	2026
Total Assets	$82.0M	$100.0M	$197.0M	$290.0M	$264.0M
Total Liabilities	$46.0M	$22.0M	$84.0M	$134.0M	$72.0M
Cash	$24.0M	$41.0M	$38.0M	$48.0M	$43.0M
Borrowings	$32.0M	$3.0M	$51.0M	$100.0M	$28.0M

Cash Flow (USD)

Metric	2022	2023	2024	2025	2026
Operating Cash Flow	$1.0M	$-22.0M	$-6.0M	$-31.0M	$-7.0M
Investing Cash Flow	$0	$35.0M	$5.0M	$-3.0M	$-31.0M
Financing Cash Flow	$-6.0M	$-28.0M	$-1.0M	$-2.0M	$-6.0M
Net Cash Flow	$-1.0M	$18.0M	$-3.0M	$10.0M	$-5.0M
Free Cash Flow	$1.0M	$-22.0M	$-7.0M	$-33.0M	$-23.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-22.44
FCF Yield	-1.83%
Quick Ratio	2.07
Interest Coverage	-41.71
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held32.69%

Institutions Held0.00%

Institutions Float Held0.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADBGFAdore Beauty Group Limited	$0.65	+0.00%	76.47	$61.07M	0.00%
GLXZGalaxy Gaming, Inc.	$1.62	+0.00%	8.60	$41.07M	0.00%
KMSWFKingmaker Footwear Holdings Limited	$0.04	+0.00%	-4.12	$26.44M	0.00%
MENEFMene Inc.	$0.12	-1.76%	19.35	$30.92M	0.00%
NLLGFNilörngruppen AB	$5.76	+0.00%	18.37	$60.19M	0.00%

About Baijin Life Science Holdings Limited

This investment holding company specializes in a comprehensive range of activities within the pearl and jewelry industry, encompassing everything from sourcing, processing, and design to manufacturing, assembly, trading, and wholesale distribution of these products. Its operations are bifurcated into two main divisions: the sale of pearls and jewelry, and strategic investment and financial services. Additionally, the company participates in real estate financial asset investments. Its global footprint includes Hong Kong, the United Kingdom, the United States, Japan, Europe, and mainland China. Originally named Man Sang Jewellery Holdings Limited, the firm adopted the identity of Affluent Partners Holdings Limited in February 2017. Established in 2014, its headquarters are situated in Central, Hong Kong.

Baijin Life Science Holdings Limited is headquartered in HK.

Baijin Life Science Holdings Limited (MNNGF) stock trades at $0.08 with a market capitalization of $74.58M. The stock is valued at a price-to-earnings (P/E) ratio of -22.39, price-to-book of 5.99, price-to-sales of 9.40. Over the past 52 weeks the stock has ranged between $0.05 and $0.08, and currently trades at its 52-week high.

On profitability, Baijin Life Science Holdings Limited generates a return on equity (ROE) of -23.23%, return on capital employed of -16.87%, an operating margin of -37.74%, a net profit margin of -42.40%.

Official website: www.baijinlifescience.com